Citigroup Inc Crinetics Pharmaceuticals, Inc. Transaction History

Citigroup Inc

$150 Billion
Q1 2024

A detailed history of Citigroup Inc transactions in Crinetics Pharmaceuticals, Inc. stock. As of the latest transaction made, Citigroup Inc holds 248,050 shares of CRNX stock, worth $11.1 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

248,050

Previous 102,311 142.45%

Holding current value

$11.1 Million

Previous $3.64 Million 218.98%

% of portfolio

0.01%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	BUY	$34.76 - $46.81 $5.07 Million - $6.82 Million	145,739 Added 142.45%	248,050 $11.6 Million
Q4 2023 Feb 09, 2024	BUY	$25.62 - $37.07 $474,969 - $687,240	18,539 Added 22.13%	102,311 $3.64 Million
Q3 2023 Nov 09, 2023	BUY	$15.97 - $30.59 $453,356 - $868,388	28,388 Added 51.26%	83,772 $2.49 Million
Q2 2023 Aug 10, 2023	SELL	$15.73 - $23.6 $761,851 - $1.14 Million	-48,433 Reduced 46.65%	55,384 $998,000
Q1 2023 May 11, 2023	BUY	$15.31 - $21.1 $841,223 - $1.16 Million	54,946 Added 112.43%	103,817 $1.67 Million

Q4 2022 Feb 09, 2023	SELL	$15.49 - $19.05 $334,816 - $411,765	-21,615 Reduced 30.67%	48,871 $894,000
Q3 2022 Nov 10, 2022	BUY	$18.11 - $22.37 $371,363 - $458,719	20,506 Added 41.03%	70,486 $1.38 Million
Q2 2022 Aug 10, 2022	BUY	$16.49 - $27.64 $569,069 - $953,856	34,510 Added 223.08%	49,980 $932,000
Q1 2022 May 12, 2022	SELL	$17.15 - $28.31 $630,313 - $1.04 Million	-36,753 Reduced 70.38%	15,470 $340,000
Q4 2021 Feb 10, 2022	BUY	$19.35 - $28.41 $550,701 - $808,548	28,460 Added 119.77%	52,223 $1.48 Million
Q3 2021 Nov 10, 2021	BUY	$16.88 - $25.23 $401,119 - $599,540	23,763 New	23,763 $500,000

Others Institutions Holding CRNX

# of Institutions

220

Shares Held

75.8M

Call Options Held

631K

Put Options Held

749K

View Full List

About Crinetics Pharmaceuticals, Inc.

Ticker CRNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,752,800
Market Cap $2.41B
Description
Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...

More about CRNX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account